For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
IL22 is a member of a group of cytokines called the IL10 family (including IL19, IL20, IL24, and IL26), a class of potent mediators of cellular inflammatory responses. IL22, ~20 kDa in size, is produced by activated DC,TH1, TH17, and NK cells acting primarily on epithelial cells such as respiratory and gut epithelial cells.. On binding to its receptor (IL22R1), which is associated to the interleukin 10 receptor 2 (IL10R2), IL22 promotes activation of multiple signals including the STAT1, STAT3, ERK, p38, and JNK pathways. IL22 can contribute to immune disease through the stimulation of inflammatory responses, S100s and defensins. In some contexts, the pro-inflammatory versus tissue-protective functions of IL22 are regulated by the often co-expressed cytokine IL17A
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Cytokine|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Unit Size||100 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...